Orchid gets FDA OK for generic antibiotic

By Elaine Rigoli

Tampa, Fla., Aug. 16 - Orchid Chemicals & Pharmaceuticals Ltd. said Wednesday that it has received approval from the Food and Drug Administration for three of its abbreviated New Drug Applications for cefotaxime for injection in various dosage forms.

The new dosages include 500 mg, 1 gm and 2 gm single-dose vials; 1 gm and 2 gm piggyback vials; and 10 gm pharmacy bulk-package vials.

Cefotaxime is the generic version of Sanofi-Aventis' antibiotic Claforan.

Orchid said it will launch this product in the United States through its exclusive distribution partner, Apotex.

Orchid is an integrated pharmaceutical company based in Chennai, India.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.